Asset Management One Co. Ltd. Cuts Stock Holdings in DaVita Inc. $DVA

Asset Management One Co. Ltd. lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 92.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,280 shares of the company’s stock after selling 16,563 shares during the quarter. Asset Management One Co. Ltd.’s holdings in DaVita were worth $145,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. NewEdge Advisors LLC boosted its stake in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Goldman Sachs Group Inc. lifted its holdings in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares in the last quarter. Cerity Partners LLC lifted its holdings in DaVita by 7.0% during the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after buying an additional 172 shares in the last quarter. Bank of Nova Scotia lifted its holdings in DaVita by 3.8% during the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after buying an additional 176 shares in the last quarter. Finally, Natixis lifted its holdings in DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after buying an additional 3,264 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA stock opened at $151.80 on Friday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The firm has a market capitalization of $10.14 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 0.54 and a beta of 0.92. The stock’s 50-day simple moving average is $150.92 and its 200-day simple moving average is $130.74.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the prior year, the business posted $2.24 EPS. DaVita’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities analysts forecast that DaVita Inc. will post 14.16 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on DVA. Truist Financial set a $158.00 price objective on shares of DaVita in a report on Thursday, February 5th. UBS Group lifted their price objective on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Barclays lifted their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $155.80.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.